Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:2.6.1.44 (
AGT
)
770
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
A new simple low ionic strength antiglobulin test (LIS-AGT) is presented for use in the antibody screening phase of pretransfusion tests. The ionic strength during the incubation phase of
LIS
-
AGT
is held between 15-17% of that of indirect
AGT
, and 8 mM EDTA is added to serum to inhibit false-positive tests. The prevalence of false-positive
LIS
-
AGT
was determined to be approximately two times higher than that observed with the indirect
AGT
. The new test was superior to the indirect
AGT
in detecting antibodies specific to Rh, Duffy, Kidd, and MNSs antigens, while the indirect
AGT
was superior in detecting antibodies specific to K and Lewis antigens. On the basis of three 51Cr red blood cell (RBC) survival studies, it was shown that antibodies reactive with
LIS
-
AGT
only decreased the long-term survival of incompatible erythrocytes, although the one-hour recovery was not affected. It appeared that antibodies reactive by
LIS
-
AGT
only can cause delayed rather than acute hemolytic transfusion reactions. The data shown indicate that the
LIS
-
AGT
is a simple and valuable addition to the pre-transfusion antibody screening test.
...
PMID:A new low ionic strength test for assessment of pretransfusion compatibility. Studies in vitro and in vivo. 685 63